Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common Marmoset (Callithrix jacchus)

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3922-3926

  Nelson, Michelle ^a   Lever, Mark S ^a   Dean, Rachel E ^a   Pearce, Peter C ^a   Stevens, Daniel J ^a   Simpson, Andrew J H ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

AIRBORNE INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FRANCISELLA TULARENSIS; LIQUID CHROMATOGRAPHY; MALE; MARMOSET; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TULAREMIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CALLITHRIX; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCISELLA TULARENSIS; MALE; OFLOXACIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TULAREMIA;

EID: 77956100621     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00390-10     Document Type: Article

References (23)

1. Aranda, E. A. 2001. Treatment of tularemia with levofloxacin. Clin. Microbiol. Infect. 7:167-168.
2. Carrasco-Portugal, M. D. C., and F. J. Flores-Murrieta. 2009. Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. Int. J. Clin. Pharmacol. Ther. 47:283-286.
3. Chien, S. C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
4. Conlan, J. W., W. Chen, H. Shen, A. Webb, and R. KuoLee. 2003. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb. Pathog. 34:239-248.
5. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, et al. 2001. Tularemia as a biological weapon-medical and public health management. JAMA 285:2763-2773. (Pubitemid 32525374)
6. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
7. Druett, H. A. 1969. A mobile form of the Henderson apparatus. J. Hyg. (Lond) 67:437-448.
8. Ellis, J., P. C. F. Oyston, M. Green, and R. W. Titball. 2002. Tularemia. Clin. Microbiol. Rev. 15:631-646.
9. Evans, M. E., D. W. Gregory, W. Schaffner, and Z. A. McGee. 1985. Tularemia: a 30-year experience with 88 cases. Medicine 64:251-269.
10. Fish, D. N. 2003. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. Expert Rev. Anti Infect. Ther. 1:371-387.
11. Hayes, E., S. Marshall, D. Dennis, and K. Feldman. 2002. Tularemia - United States, 1990-2000. MMWR Morb. Mortal. Wkly. Rep. 51:181-184.
12. Hemeryck, A., R. N. V. S. Mamidi, M. Bottacini, D. Macpherson, M. Kao, and M. F. Kelley. 2006. Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the rhesus monkey. Xenobiotica 36:597-613.
13. Hepburn, M. J., and A. J. Simpson. 2008. Tularemia: current diagnosis and treatment options. Expert Rev. Anti Infect. Ther. 6:231-240.
14. Kaiser, A. B., D. Rieves, A. H. Price, M. R. Gelfand, R. E. Parrish, M. D. Decker, and M. E. Evans. 1985. Tularemia and rhabdomyolysis. JAMA 253:241-243.
15. Kao, L. M., K. Bush, R. Barnewall, J. Estep, F. W. Thalacker, P. H. Olson, G. L. Drusano, N. Minton, S. Chien, A. Hemeryck, and M. F. Kelley. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542.
16. Kelly, D. J., J. D. Chulay, P. Mikesell, and A. M. Friedlander. 1992. Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J. Infect. Dis. 166:1184-1187.
17. Klimpel, G. R., T. Eaves-Pyles, S. T. Moen, J. Taormina, J. W. Peterson, A. K. Chopra, D. W. Niesel, P. Carness, J. L. Haithcoat, M. Kirtley, and A. B. Nasr. 2008. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 26:6874-6882.
18. Lever, M. S., A. J. Stagg, M. Nelson, P. Pearce, D. J. Stevens, E. A. Scott, A. J. H. Simpson, and M. J. Fulop. 2008. Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol. 89:171-179.
19. Li, F., P. Nandy, S. Chien, G. J. Noel, and C. W. Tornoe. 2010. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob. Agents Chemother. 54:375-379.
20. Limaye, A. P., and C. J. Hooper. 1999. Treatment of tularemia with fluoroquinolones: two cases and review. Clin. Infect. Dis. 29:922-924.
21. Nelson, M., M. S. Lever, V. L. Savage, F. J. Salguero, P. C. Pearce, D. J. Stevens, and A. J. H. Simpson. 2009. Establishment of lethal inhalational infection with Francisella tularensis (tularemia) in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol. 90:109-118.
22. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.
23. Yarbrough, L. W., J. L. Tollett, R. D. Montrey, and R. J. Beattie. 1984. Serum biochemical, hematological and body measurement data for common marmosets (Callithrix jacchus jacchus). Lab. Anim. Sci. 34:276-280.